|Commissioned research: Combatting the US opioid epidemic, 27 June 2018|
|Orexo is a fully integrated, speciality pharmaceuticals company based in Uppsala, Sweden, and with commercial operations in the US. Its 2017 revenue stemmed mostly from opioid addiction (76%) and breakthrough cancer pain (18%) drugs, based on its proprietary formulation technology platform. Orexo had an EBITDA margin of 12% in 2017, which we estimate will increase to 17% by 2019.
Marketing material commissioned by Orexo.
To learn more on Commissioned Research, please click here
Nordea Markets is the name of the Markets departments of Nordea Bank AB (publ) and its branches Nordea Danmark, filial af Nordea Bank AB (publ), Sverige, Nordea Bank AB (publ), filial i Finland and Nordea Bank AB (publ), filial i Norge. The information provided herein is intended for the sole use of the intended recipient. The views and other information provided herein are the current views of Nordea Markets as of the date of this document and are subject to change without notice. The views have been provided solely based on the information made available to Nordea Markets and for the purposes of presenting the services made available by Nordea Markets. This notice does not substitute the judgement of the recipient. Nordea Markets is not and does not purport to be an adviser as to legal, taxation, accounting or regulatory matters in any jurisdiction. Relevant professional advice should always be obtained before making any investment or credit decision. This document may not be reproduced, distributed or published for any purpose without the prior written consent from Nordea Markets. This transmission is intended solely for the person or entity to whom it is addressed. It may contain privileged and confidential information. If you are not the intended recipient, please be notified that any dissemination, distribution or copying is strictly prohibited. If you have received this transmission by mistake, please let us know and then delete it from your system.